Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals is a clinical-stage life science company with a groundbreaking synthetic chemistry technology platform that has the power to deliver solutions to the global health crisis caused by antibiotic resistance. Since the company’s inception in 2006, Tetraphase has developed a robust antibiotic franchise that offers the potential to dramatically improve the treatment of both broad and selective spectrum bacterial infections.
Pipeline   Partnerships


Tetraphase's clinical-stage antibiotic candidates offer significant differentiation from drugs that are currently on the market or in development by other companies. Tetraphase's lead broad spectrum candidate is in Phase 2 clinical trials, and two other differentiated candidates are poised to enter the clinic in the first half of 2011. More >>


With its unparalleled antibiotics franchise, Tetraphase offers significant value for leading pharmaceutical companies. If you are interested in partnering with Tetraphase, More >>




 

      Legal Notes / Privacy © 2012 Tetraphase Pharmaceuticals  

Tetraphase's lead candidates have the potential to treat a broad range of serious bacterial infections. This provides a tremendous opportunity to address the global health crisis caused by the increasing number of infections resistant to currently used antibiotics.

The Tetraphase proprietary drug engine has produced more than 2,600 proprietary compounds with novel molecular structures, reinvigorating one of the best known, safest and most efficacious classes of antibiotics ever discovered.

In just five years, Tetraphase has developed a strong pipeline with a lead broad spectrum antibiotic candidate in Phase 2 clinical trials, another drug candidate in Phase 1, and several additional candidates in preclinical development.